anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A cationic group-containing copolymer is provided which possesses excellent thixotropy and exhibits high adsorbability to the skin, hair, etc. and, when incorporated as a thickener in cosmetic articles, manifests a very satisfactory tactile sensation. The cationic group-containing copolymer is characterized in that the viscosity at 25° C. of the aqueous solution prepared by incorporating the copolymer in deionized water at a concentration of 0.5 wt. % is in the range of 0.3-20 Pa·sec. at a shear rate of 1 sec -1  and in the range of 0.01-5 Pa·sec. at a shear rate of 10 sec -1  and the viscosity at a shear rate of 1 sec -1  is higher than the viscosity at a shear rate of 10 sec -1 . This cationic group-containing copolymer is obtained by particularly using a cationic group-containing vinyl monomer, a hydrophilic nonionic group-containing vinyl monomer such as N,N-dimethyl (meth)acrylamide or N,N-diethyl (meth)acrylamide, and a cross-linking vinyl monomer containing at least two vinyl groups in the molecular unit thereof as essential component monomers and radically polymerizing the essential component monomers. A thickener made of the copolymer is also disclosed.
The invention relates to the field of pharmaceutical chemistry, and discloses a method for preparing prasugrel, and prasugrel hydrochloride novel crystal forms. According to the invention, acetylation is carried out in a low-boiling-point and low-toxicity solvent, such that prasugrel is prepared. Applications of high-boiling-point and high-toxicity solvents such as toluene and acetonitrile are avoided, such that a technical problem of thermal instability of prasugrel is solved, prasugrel loss is reduced, and yield is improved. When the method is used in preparing prasugrel, the yields are higher than 85%, and purities are higher than 99.5%. The prepared prasugrel can be used for preparing any pharmaceutically acceptable prasugrel salt. The basically-pure prasugrel hydrochloride novel crystal forms H1, H2, and H3 have excellent performances in oral absorbability, metabolism activating performance, and platelet aggregation inhibiting activity. The crystal forms have low toxicity, good storage stability, and good processing stability. The novel crystal forms of prasugrel hydrochloride can be used for preparing medicines used for treating diseases caused by thrombosis or embolism.
Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will operate at a 50% duty cycle.
Nonmass lesions (NMLs) on breast US are defined as discrete areas of altered echotexture compared to surrounding breast tissue and lack the 3-dimensionality of a mass. They are not a component of American College of Radiology BI-RADS, but they are a finding type included in the Japan Association of Breast and Thyroid Sonology lexicon. Use of the NML finding is routine in many Asian practices, including the Samsung Medical Center and Seoul National University Hospital, and their features and outcomes have been investigated in multiple studies. Nonmass lesions are most often observed when US is used to evaluate mammographic asymmetries, suspicious calcifications, and nonmass enhancement on MRI and contrast-enhanced mammography. Nonmass lesions can be described by their echogenicity, distribution, presence or absence of associated calcifications, abnormal duct changes, architectural distortion, posterior shadowing, small cysts, and hypervascularity. Malignant lesions, especially ductal carcinoma in situ, can manifest as NMLs on US. There is considerable overlap between the US features of benign and malignant NMLs, and they also must be distinguished from normal variants. The literature indicates that NMLs with linear or segmental distribution, associated calcifications, abnormal duct changes, posterior shadowing, and hypervascularity are suggestive of malignancy, whereas NMLs with only interspersed small cysts are usually benign fibrocystic changes. In this article, we introduce the concepts of NMLs, illustrate US features suggestive of benign and malignant etiologies, and discuss our institutional approach for evaluating NMLs and an algorithm that we use to guide interpretation in clinical practice.
PURPOSE:An active oxygen removing agent, containing 3-hydroxyquinurenine, salt, ester or acylated material thereof as an active ingredient, useful for preventing and treating various diseases caused by active oxygen and having low toxicity. CONSTITUTION:An active oxygen removing agent, containing 3- hydroxyquinurenine, a salt, ester or acylated material thereof as an active ingredient. It has been elicited that the active oxygen is closely related to peroxidation, aging, inflammation, carcinogenesis, etc., of a cell membrane lipid and it is recognized that 3-hydroxyquinurenine which is one kind of in vivo metabolites has active oxygen removing action as a substance having the above-mentioned action. The toxicity thereof is very low. There are D- isomer, L-isomer and racemic modification of 3-hydroxyquinurenine and all of them are usable as an active ingredient of the active oxygen removing agent. The dose thereof is normally 1-3,000mg/day for human adults.
Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
FIELD: medicine, immunology. SUBSTANCE: method involves magnetic powder treatment, preparing an aqueous phase followed by emulsion polymerization of an aqueous phase to organic phase by gaseous nitrogen flow. Magnosorbent granules were washed, activated with glutaric aldehyde and ligand is added. Preliminary treatment of magnetic powder is carried out by its washing with acetone, distilled water followed by phosphating. Aqueous phase is prepared for three stages: wet dispersing in acetone, treatment with detergent and washing with distilled water. Obtained granules can be used for antigenic material incorporation in immunological investigations and for selective microorganism concentration. EFFECT: improved hydrophility and stability of granules. 1 tbl
The present invention relates generally to a method of modulating cellular activity and to agents for use therein. More particularly, the present invention provides a method of modulating cellular activity by modulating intracellular translocation of sphingosine kinase to the cell membrane. In a related aspect, the present invention provides a method of modulating sphingosine kinase mediated signalling via modulation of its intracellular translocation and agents for use therein. The present invention still further extends to sphingosine kinase variants and to functional derivatives, homologues and analogues thereof, exhibiting ablated or reduced capacity to undergo translocation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate cellular functional activity and/or aberrant, unwanted or otherwise inappropriate sphingosine kinase mediated signalling. The present invention is further directed to methods for identifying and/or designing agents capable of modulating sphingosine kinase intracellular translocation.
A medicine composition for treating xenorhabdus infection of livestock and poultry is disclosed. The medicine composition comprises following raw material medicines by weight: 120-180 parts of dandelion, 120-180 parts of purslane herb, 120-180 parts of Chinese pulsatilla root, 60-120 parts of sophora alopecuroides, 60-120 parts of wolfiporia extensa, 60-120 parts of cablin patchouli herb, 30-90 parts of angelica dahurica, 60-120 parts of areca peel, 30-90 parts of dried tangerine peel, 30-90 parts of cortex magnoliae officinalis, 30-90 parts of talc, 30-90 parts of radix et rhizoma rubiae and 20-40 parts of licorice. The medicine composition is characterized by being strong in effects, not liable in generation of drug resistance, and low in side and toxic effects, and has good curative effects for treating xenorhabdus infection of livestock and poultry. The medicine composition is simple in preparing process. The raw materials are cheap and easily available herbal medicines. The medicine composition is low in cost and suitable for veterinary use popularization.
Adults

The recommended starting and target dosage of OPIPZA for the treatment of schizophrenia in adults is 10 mg or 15 mg once daily. Aripiprazole has been systematically evaluated and shown to be effective in a dose range of 10 mg to 30 mg per day; however, doses higher than 10 mg or 15 mg per day were not more effective than 10 mg or 15 mg per day. Dosage increases should generally not be made before 2 weeks, the time needed to achieve steady-state [see Clinical Studies (14.2)].

Pediatric Patients Ages 13 Years and Older

The recommended starting dosage of OPIPZA for the treatment of schizophrenia in pediatric patients 13 years and older is 2 mg once daily. The recommended target dosage of OPIPZA is 10 mg once daily. Aripiprazole was studied in pediatric patients 13 to 17 years of age with schizophrenia at daily dosages of 10 mg and 30 mg. The starting daily dosage in these patients was 2 mg, which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days. Subsequent dose increases should be administered in 5 mg increments. The 30 mg per day dosage was not shown to be more efficacious than the 10 mg per day dosage.
Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
VAFSEO increases the risk of arterial and venous thrombotic events, that may be fatal, including myocardial infarction, stroke, venous thromboembolism and vascular access thrombosis [see Boxed Warning, Adverse Reactions (6.1)]. Patients with cardiovascular or cerebrovascular disease are at increased risk of these events. Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO.

A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks. Targeting a hemoglobin level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with ESAs, which also increase erythropoietin levels.

No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. Adherence to dosing and hemoglobin monitoring recommendations is important to avoid excessive erythropoiesis [see Dosage and Administration (2.4)].

Advise patients to seek immediate medical attention if they develop signs or symptoms of myocardial infarction, stroke, venous thromboembolism, or thrombosis of vascular access. Evaluate and manage promptly if these occur.
Patients taking carbidopa/levodopa alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living, including the operation of motor vehicles which have resulted in accidents. Although many patients reported somnolence while on dopaminergic medications, some perceived that they had no warning signs (sleep attack), such as excessive drowsiness, and believed that they were alert immediately prior to the event. Sudden onset of sleep has been reported to occur more than one year after the initiation of treatment.

It has been reported that falling asleep while engaged in activities of daily living usually occurs in a setting of pre-existing somnolence, although some patients may not give such a history. For this reason, prescribers should reassess patients for drowsiness or sleepiness in DHIVY-treated patients, especially since some of the events occur well after the start of treatment. Prescribers should be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.

Before initiating treatment with DHIVY, advise patients about the potential to develop drowsiness and ask specifically about factors that may increase the risk for somnolence with DHIVY such as the use of concomitant sedating medications and the presence of sleep disorders. Consider discontinuing DHIVY in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating, etc.). If treatment with DHIVY continues, advise patients not to drive and to avoid other potentially dangerous activities that might result in harm if the patients become somnolent. There is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.
INTRODUCTION: Axial spondyloarthritis (axSpA) is a heterogeneous disease that can be represented by radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA). This study aimed to evaluate the relationship between the markers of inflammation and bone turnover in r-axSpA patients and nr-axSpA patients.
METHODS: A cross-sectional study included 29 r-axSpA patients, 10 nr-axSpA patients, and 20 controls matched for age and sex. Plasma markers related to bone remodeling such as human procollagen type 1 N-terminal propeptide (P1NP), sclerostin, tartrate-resistant acid phosphatase 5b (TRACP5b), receptor activator of nuclear factor kappa B ligand (RANKL), and osteoprotegerin (OPG) were measured by an ELISA kit. A panel of 92 inflammatory molecules was analyzed by proximity extension assay.
RESULTS: R-axSpA patients had decreased plasma levels of P1NP, a marker of bone formation, compared to controls. In addition, r-axSpA patients exhibited decreased plasma levels of sclerostin, an anti-anabolic bone hormone, which would not explain the co-existence of decreased plasma P1NP concentration; however, sclerostin levels could also be influenced by inflammatory processes. Plasma markers of osteoclast activity were similar in all groups. Regarding inflammation-related molecules, nr-axSpA patients showed increased levels of serum interleukin 13 (IL13) as compared with both r-axSpA patients and controls, which may participate in the prevention of inflammation. On the other hand, r-axSpA patients had higher levels of pro-inflammatory molecules compared to controls (i.e., IL6, Oncostatin M, and TNF receptor superfamily member 9). Correlation analysis showed that sclerostin was inversely associated with IL6 and Oncostatin M among others.
CONCLUSION: Altogether, different inflammatory profiles may play a role in the development of the skeletal features in axSpA patients particularly related to decreased bone formation. The relationship between sclerostin and inflammation and the protective actions of IL13 could be of relevance in the axSpA pathology, which is a topic for further investigation.
The present invention relates to a nanopowder hydrogel patch including a displaying unit which indicates whether the patch is utilized or not. The nanopowder hydrogel path includes a hydrogel layer, an adhesive patch formed on the hydrogel layer, and the displaying unit which is formed on the adhesive patch and includes a discoloration unit with thermo-pigment. The color of the discoloration unit is changed by a temperature increase of the hydrogel layer being in contact with a skin when the patch is attached on the skin. The nanopowder hydrogel patch according to the present invention maintains the difference of temperatures of the skin and the hydrogel layer by 4-7°C, thereby enabling a user feel good when attaching the patch on the skin and obtaining an excellent cooling effect. Furthermore, the temperature difference is visually provided via the displaying unit attached on the patch so that a user can conveniently check the heat absorption by the patch or the replacement timing of the patch. [Reference numerals] (31) non-attachement;(32) in use
Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24°C and 40-50% (relative humidity) for 20 minutes. After 20 minutes, the temperature was maintained at 22°C and 40-50% (relative humidity) for 15 minutes, and an occlusion foot test was conducted (5 minutes ''baseline'' phase, 5 minutes ''occlusion'' phase, and 5 minutes ''release'' phase), to observe any hemodynamic changes in the foot.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. 

###  Advanced Renal Disease

No information is available from controlled clinical studies regarding the use of meclofenamate sodium in patients with advanced renal disease. Therefore, treatment with meclofenamate sodium is not recommended in these patients with advanced renal disease. If meclofenamate sodium therapy must be initiated, close monitoring of the patient's renal function is advisable.
Detailed description: Robot assisted radical prostatectomy (RARP) and external beam radiotherapy (EBRT) combined with Androgen Deprivation Therapy (ADT) are widely used treatment modalities for high-risk non-metastatic prostate cancer (HR-PCa). Both treatments are associated with adverse effects and can have a great impact on health-related quality of life (HRQoL). To date there is no consensus on which of both is the optimal treatment for men with HR-PCa, as it is unclear which treatment is superior in terms of HRQoL, cost-effectiveness, progression-free survival (PFS) and distant metastases-free survival (DMFS). This is reflected in substantial variation between individual hospitals in the utilization of both treatment options that is not explained by patient- and tumor characteristics or patient preferences. In the RECOVER study we aim to address this knowledge gap. The insights gained can be used to tailor recommendations in (national) guidelines and in shared decision-making tools. This allows healthcare professionals to better inform their patients and allows patients to make well-informed choices.
The invention discloses an application of a gnat host defensin peptide Siba. The application of the Banana gnat host defense peptide Siba in preparing a drug for resisting Zika virus infection diseases; the amino acid sequence of the gnat host defense peptide Siba is as follows: KINKQKIKNGAKKALGVASKVAPVVAAFAR-NH  2 . The invention takes host defense peptide Siba from gnat banna as a research object, and aims to elucidate the role of Siba3 in ZIKV infection. We have found that Siba can significantly inhibit ZIKV infection in vitro and also can significantly inhibit ZIKV infection in vivo, and has both prevention and treatment effects. Our results show that Siba can directly act on ZIKV, destroy viral envelope, induce viral genome to leak, thereby inactivating viral particles; siba3 can also reduce the susceptibility of host cells to Zika virus. The combination of the molecular weight is small, the structure is simple, and therefore, the method has wide development and application prospects.
Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the "trauma and depression in late preterm parents study" (TraDelPP) conducted 2010 to 2011.
OBJECTIVE: Iliac branch devices (IBDs) have shown good results but there is little evidence for the risk of internal iliac artery (IIA) endoleak, so there are no clear recommendations on the maximum diameter it should be. Based on limited evidence, it was hypothesised that an IIA of ≥ 11 mm in diameter presents an increased risk of type Ic endoleak.
METHODS: This was a single centre, retrospective case control study. Patients undergoing an IBD with the main trunk of the IIA as the target vessel, between 2015 and 2021, were identified. Two groups were created: those with a main trunk diameter of < 11 mm; and those with a diameter of ≥ 11 mm. Technical success, freedom from type Ic endoleak, and re-intervention rates were compared. A receiver operating characteristic (ROC) curve was performed to show a cutoff IIA diameter value for risk of type Ic endoleak. Multivariate analysis was performed to assess the risk of type Ic endoleak and the presence of calcification, stenosis, and landing zone length in the IIA.
RESULTS: There were 182 IBDs identified. The dilated IIA group (54 IBDs) had significantly lower technical success (91% vs. 98.4%; p = .002), lower freedom from type Ic endoleak (77% vs. 97.1% at 24 months; p = .001), and lower freedom from re-interventions (70% vs. 92.4% at 24 months; p = .002). The ROC curve showed that 10.5 mm was the cutoff diameter for type Ic endoleak. Moderate or severe calcification as well as landing zone length < 5 mm also correlated with type Ic endoleak.
CONCLUSION: IBDs have a statistically significantly higher rate of technical failure, lower freedom from type Ic endoleak, and lower freedom from re-intervention when the IIA is ≥ 11 mm in diameter.
Participants rested under thermoneutral conditions for 30 min, which was then followed by exposure to \~ 9°C air temperature for a maximum of 1 hour. Same duration as matched European individuals.
<P>PROBLEM TO BE SOLVED: To provide a method for proliferating a spermatogonial stem cell in which influence of uncertain factor is eliminated.  <P>SOLUTION: The method for proliferating the spermatogonial stem cell comprises culturing the spermatogonial stem cell in feeder-free or serum-free condition. The spermatogonial stem cell can efficiently be proliferated even in the absence of a feeder cell or serum and influence of uncertain factor can be eliminated by using the proliferation method. As a result, the spermatogonial stem cell can more stably and more simply be proliferated in a state in which ability as the spermatogonial stem cell is kept, compared with a conventional method. Risk of infectious disease derived from a heterozoic in clinical application of the spermatogonial stem cell. Consequently, the proliferation method is useful for preparation of gene-modified animals (transgenic animal, gene deletion animal, etc.), a method for treating male sterility, development of therapeutic agent of male sterility and research for gene therapy in germ cell level and development, etc., of medicines.  <P>COPYRIGHT: (C)2006,JPO&NCIPI